Corcept drops after US FDA declines to approve drug for rare hormonal disorder

Corcept Therapeutics Incorporated

31/12/2025 13:30

** Shares of drugmaker Corcept Therapeutics CORT.O fall 38.7% to $48.39 premarket

** CORT says U.S. FDA has declined to approve its hormone-blocking oral therapy, relacorilant, for the treatment of a rare hormonal disorder

** FDA says "it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness" - CORT

** Co was testing relacorilant to treat Cushing's syndrome, also known as hypercortisolism, which occurs when the body is exposed to high cortisol activity

** As of last close, stock up 39.3% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))